MDT

+ Watchlist + Portfolio

Medtronic plc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $86.44
52-Week Range: $73.31 – $106.33
Market Cap: $110.49B
P/E (TTM): 21.28
EPS (TTM): 4.06
Dividend Yield: 3.33%

Advanced Metrics

Price/Book: 2.20
PEG Ratio: 1.55
Return on Equity: 10.65%
Return on Assets: 5.12%
Gross Margin: 65.27%
Operating Margin: 19.33%
Profit Margin: 13.93%
Current Ratio: 2.07
Debt/Equity: 0.55
Total Debt: $28.15B
Free Cash Flow: $5.41B
Revenue Growth: 13.70%
Earnings Growth: 40.70%
Enterprise Value: $130.44B

MDT Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$31.23B	$32.36B	$33.54B	$36.36B
Cost of Revenue	$10.72B	$11.22B	$11.63B	$12.72B
Gross Profit	$20.51B	$21.15B	$21.91B	$23.64B
Research & Development	$2.70B	$2.73B	$2.73B	$2.87B
Selling, General & Admin	$10.41B	$10.74B	$10.85B	$11.78B
Operating Expenses	$14.68B	$15.63B	$15.37B	$16.82B
Operating Income	$5.83B	$5.52B	$6.54B	$6.83B
EBITDA	$8.70B	$8.20B	$9.22B	$9.81B
Pretax Income	$5.36B	$4.84B	$5.63B	$6.14B
Income Tax	$1.58B	$1.13B	$936.00M	$1.30B
Net Income	$3.76B	$3.68B	$4.66B	$4.80B
Diluted EPS	2.82	2.76	3.61	—
Diluted Shares	1.33B	1.33B	1.29B	—

MDT Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$1.54B	$1.28B	$2.22B	$1.95B
Receivables	$6.00B	$6.13B	$6.51B	$6.64B
Inventory	$5.29B	$5.22B	$5.48B	$5.95B
Current Assets	$21.68B	$21.93B	$23.81B	$24.79B
Total Assets	$90.95B	$89.98B	$91.68B	$93.03B
Current Liabilities	$9.05B	$10.79B	$12.88B	$11.66B
Long-Term Debt	$24.29B	$23.88B	$25.59B	$26.12B
Total Debt	$24.36B	$25.02B	$28.52B	$27.96B
Total Liabilities	$39.28B	$39.56B	$43.42B	$42.96B
Retained Earnings	$30.39B	$30.40B	$31.48B	$32.64B
Shareholders' Equity	$51.48B	$50.21B	$48.02B	$49.46B
Working Capital	$12.62B	$11.15B	$10.94B	$13.13B
Net Debt	$22.76B	$23.68B	$26.24B	$25.95B

MDT Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	$6.04B	$6.79B	$7.04B	$7.33B
Capital Expenditure	-$1.46B	-$1.59B	-$1.86B	-$1.90B
Free Cash Flow	$4.58B	$5.20B	$5.18B	$5.43B
Depreciation & Amortisation	$2.70B	$2.65B	$2.86B	$2.96B
Stock-Based Compensation	$355.00M	$393.00M	$429.00M	$457.00M
Investing Cash Flow	-$3.49B	-$2.37B	-$1.94B	-$2.93B
Financing Cash Flow	-$4.96B	-$4.45B	-$4.36B	-$4.75B
Dividends Paid	-$3.62B	-$3.67B	-$3.59B	-$3.64B
Share Repurchases	-$645.00M	-$2.14B	-$3.23B	-$1.03B
Net Change in Cash	-$2.41B	-$29.00M	$746.00M	-$354.00M

MDT Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$8.93B	$8.58B	$8.96B	$9.02B	$9.81B
Cost of Revenue	$3.15B	$3.00B	$3.06B	$3.26B	$3.40B
Gross Profit	$5.78B	$5.58B	$5.90B	$5.76B	$6.41B
Research & Development	$684.00M	$726.00M	$754.00M	$722.00M	$671.00M
Selling, General & Admin	$2.72B	$2.81B	$2.96B	$2.96B	$3.06B
Operating Expenses	$3.98B	$4.06B	$4.20B	$4.15B	$4.40B
Operating Income	$1.80B	$1.52B	$1.70B	$1.60B	$2.01B
EBITDA	$2.27B	$2.23B	$2.52B	$2.33B	$2.73B
Pretax Income	$1.26B	$1.30B	$1.60B	$1.40B	$1.83B
Income Tax	$199.00M	$255.00M	$215.00M	$254.00M	$575.00M
Net Income	$1.06B	$1.04B	$1.37B	$1.14B	$1.24B
Diluted EPS	0.82	0.81	1.07	0.89	0.96
Diluted Shares	1.29B	1.29B	1.29B	1.29B	1.29B

MDT Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$2.22B	$1.27B	$1.28B	$1.15B	$1.95B
Receivables	$6.51B	$6.26B	$6.39B	$6.36B	$6.64B
Inventory	$5.48B	$5.89B	$6.16B	$6.31B	$5.95B
Current Assets	$23.81B	$23.22B	$24.00B	$24.07B	$24.79B
Total Assets	$91.68B	$90.97B	$91.35B	$91.48B	$93.03B
Current Liabilities	$12.88B	$11.53B	$9.94B	$9.49B	$11.66B
Long-Term Debt	$25.59B	$26.13B	$27.63B	$27.82B	$26.12B
Total Debt	$28.52B	$28.61B	$29.10B	$28.07B	$27.96B
Total Liabilities	$43.42B	$42.84B	$42.49B	$42.29B	$42.96B
Retained Earnings	$31.48B	$31.61B	$32.07B	$32.30B	$32.64B
Shareholders' Equity	$48.02B	$47.89B	$48.65B	$48.98B	$49.46B
Working Capital	$10.94B	$11.69B	$14.06B	$14.58B	$13.13B
Net Debt	$26.24B	$27.29B	$27.76B	$26.87B	$25.95B

MDT Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$2.53B	$1.09B	$925.00M	$2.74B	$2.57B
Capital Expenditure	-$459.00M	-$504.00M	-$468.00M	-$444.00M	-$488.00M
Free Cash Flow	$2.07B	$584.00M	$457.00M	$2.30B	$2.08B
Depreciation & Amortisation	$840.00M	$748.00M	$745.00M	$749.00M	$716.00M
Stock-Based Compensation	$89.00M	$86.00M	$182.00M	$94.00M	$95.00M
Investing Cash Flow	-$490.00M	-$719.00M	-$482.00M	-$816.00M	-$917.00M
Financing Cash Flow	-$1.34B	-$1.38B	-$395.00M	-$2.09B	-$888.00M
Dividends Paid	-$897.00M	-$910.00M	-$910.00M	-$911.00M	-$908.00M
Share Repurchases	-$274.00M	-$123.00M	-$372.00M	-$105.00M	-$435.00M
Net Change in Cash	$695.00M	-$1.01B	$48.00M	-$159.00M	$769.00M

Market Snapshot

About

Medtronic plc is one of the largest global medical technology companies, developing and manufacturing medical devices and therapies that treat chronic diseases and acute conditions. The company operates across cardiovascular, medical surgical, neuroscience, and diabetes segments, serving physicians, hospitals, and patients in over 150 countries.